The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.
作者信息
Loomba Rohit, Adams Leon A
机构信息
Nonalcoholic Fatty Liver Disease Research Center, Department of Medicine, University of California, San Diego, La Jolla, CA.
Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA.
出版信息
Hepatology. 2019 Dec;70(6):1885-1888. doi: 10.1002/hep.30946.
Abstract
摘要
相似文献
1
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.
Hepatology. 2019 Dec;70(6):1885-1888. doi: 10.1002/hep.30946.
2
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Hepatology. 2019 Dec;70(6):1913-1927. doi: 10.1002/hep.30664. Epub 2019 May 28.
3
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Gastroenterology. 2021 Apr;160(5):1608-1619.e13. doi: 10.1053/j.gastro.2020.12.003. Epub 2020 Dec 8.
4
Epidemiology and natural history of non-alcoholic fatty liver disease.
Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012. Epub 2016 Jan 29.
5
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.
6
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
7
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.
8
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):970-985. doi: 10.1016/S2468-1253(20)30252-1. Epub 2020 Aug 5.
9
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
J Hepatol. 2020 May;72(5):828-838. doi: 10.1016/j.jhep.2019.12.008. Epub 2019 Dec 17.
10
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
J Med Econ. 2024 Jan-Dec;27(1):1108-1118. doi: 10.1080/13696998.2024.2393952. Epub 2024 Aug 22.
引用本文的文献
1
Cross-sectional Study of Resident Physician Knowledge and Perceptions Regarding MASLD in Canada.
Can Liver J. 2025 Feb 25;8(1):8-17. doi: 10.3138/canlivj-2024-0009. eCollection 2025 Feb.
2
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis.
Gastroenterol Rep (Oxf). 2025 May 2;13:goaf037. doi: 10.1093/gastro/goaf037. eCollection 2025.
3
The importance of patient engagement in the multimodal treatment of MASLD.
Commun Med (Lond). 2025 May 1;5(1):148. doi: 10.1038/s43856-025-00871-1.
4
Identification of pyroptosis-associated gene to predict fibrosis and reveal immune characterization in non-alcoholic fatty liver disease.
Sci Rep. 2025 Apr 29;15(1):14944. doi: 10.1038/s41598-025-96158-5.
5
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.
J Clin Med. 2025 Apr 16;14(8):2750. doi: 10.3390/jcm14082750.
6
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
7
Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma.
Medicina (Kaunas). 2025 Jan 7;61(1):88. doi: 10.3390/medicina61010088.
8
Differential aging trends among candidates for liver transplant with and without HCC.
Liver Transpl. 2025 Jun 1;31(6):716-726. doi: 10.1097/LVT.0000000000000568. Epub 2025 Jan 20.
9
MR Elastography Using the Gravitational Transducer.
Sensors (Basel). 2024 Dec 17;24(24):8038. doi: 10.3390/s24248038.
10
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study.
J Comp Eff Res. 2024 Dec;13(12):e240096. doi: 10.57264/cer-2024-0096. Epub 2024 Nov 22.
本文引用的文献
1
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Hepatology. 2019 Dec;70(6):1913-1927. doi: 10.1002/hep.30664. Epub 2019 May 28.
2
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4.
3
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
Liver Int. 2019 May;39(5):924-932. doi: 10.1111/liv.13974. Epub 2019 Feb 21.
4
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Gastroenterology. 2018 Oct;155(4):1140-1153. doi: 10.1053/j.gastro.2018.07.006. Epub 2018 Jul 7.
5
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.
Am J Gastroenterol. 2018 Nov;113(11):1649-1659. doi: 10.1038/s41395-018-0088-6. Epub 2018 Jun 8.
6
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Gastroenterology. 2018 Aug;155(2):443-457.e17. doi: 10.1053/j.gastro.2018.04.034. Epub 2018 May 5.
7
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
8
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.
9
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24.
10
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.
Hepatology. 2003 Aug;38(2):420-7. doi: 10.1053/jhep.2003.50320.
Zotero 插件